All Immuno Content

Bringing you the latest research in immuno-oncology, autoimmunity, therapeutic modalities and more, through a range of Speaker Interviews, Industry Insights, and Expert Opinions.

Commentary
The activation of GPR65 on immune cells by the acidic tumour microenvironment and the resultant immunosuppression may be one of the principal reasons many cancers do not respond to current T Cell checkpoint therapies. Chief Executive Officer Stuart Hughes delves into some of Pathios Therapeutics recent developments in macrophage conditioning and its promise to enable a successful anti-tumour immune response.
By Tia Byer |
01 November 2021
Tumour Microenvironment
Video Content
Webinar
Hosted by Robert Power, Manager, Product Management at Personalis, Inc
21 May 2020
Tumour Microenvironment
Video Content
Webinar
Russell LaMontagne, Co-Founder and Chief Executive Officer, Boston Immune Technologies and Therapeutics
24 April 2020
Tumour Microenvironment
Ruth Seelige, Senior Scientist, Pfizer
08 October 2019
Tumour Microenvironment
Video Content
Webinar
Russell LaMontagne, Chief Executive Officer, Boston Immune Technologies & Therapeutics Inc
11 October 2018
Tumour Microenvironment

Search by Keyword

Filter by Subject Area

Filter by Content Type

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Immuno

Submit your details to receive the monthly newsletter & to be kept up to date about relevant events, monthly discussion groups and portal membership offers. You may opt-out at any time. Please check our Privacy Policy to see how Oxford Global protects and manages your data.